Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    9647875 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Terminated ACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-cell Lymphoma
Condition: Diffuse Large Cell Lymphoma
Interventions: Drug: rituximab;   Drug: doxorubicin;   Drug: cyclophosphamide

Study has passed its completion date and status has not been verified in more than two years.